Selank Research Guide

Compound Guide

Selank — Anxiolytic Tuftsin Analogue (TP-7)

7-AA peptide · Approved Russia for anxiety/neurasthenia · SubQ or intranasal

Quick Start

What It Is

Selank (also designated TP-7) is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a tuftsin analogue (tuftsin = immunomodulatory tetrapeptide Thr-Lys-Pro-Arg) extended with additional amino acids to improve stability. Approved in Russia as a prescription drug for generalised anxiety disorder and neurasthenia.

Research Dosing

SubQ: 250–500 mcg/day. Intranasal: 600–2,700 mcg/day split into 2–3 administrations. The intranasal route is favoured in Russian clinical research; SubQ is more common in Western research contexts. Half-life is short (~1–3 min plasma, but effects persist longer due to downstream signalling).

Cycle Structure

4 weeks on / 4 weeks off for SubQ protocols. Intranasal research protocols typically use 14–21 day courses followed by a washout period before resuming. The on/off structure is used to prevent tolerance.

Regulatory Status

Approved prescription drug in Russia for anxiety and neurasthenia. No FDA approval. No ClinicalTrials.gov Phase 1–3 program registered as of 2026. Not on WADA banned list. For research purposes only outside Russia.

Dosing Protocol

Route	Dose	Frequency	Duration	Notes
SubQ	250–500 mcg	Once daily	4 weeks on, 4 weeks off	Western research standard
Intranasal	200–900 mcg per administration	2–3× daily	14–21 day course + washout	Russian clinical standard; 2–3 sprays of 200–300 mcg each

Supplies & Reconstitution (SubQ)

Reconstitution Math — 10 mg Vial (3 mL BAC)

Target Dose	Units (U-100)	Doses / Vial
100 mcg	3 units	100
200 mcg	6 units	50
300 mcg	9 units	33.3
500 mcg	15 units	20
600 mcg	18 units	16.7
1000 mcg	30 units	10

Reconstitute the 10 mg vial with 3.0 mL bacteriostatic water (sold separately) → 3.33 mg/mL (3,333 mcg/mL). U-100 syringe = 100 units per mL. Swirl gently — do not shake. Refrigerate 2–8°C.

Reconstitution Steps

Warm the vial

Allow lyophilised vial to reach room temperature before reconstitution.

Swab and draw

Alcohol swab both vial tops. Draw required BAC water volume.

Inject along the wall

Run BAC water slowly along the inside vial wall. Do not jet onto the powder.

Swirl gently

Swirl until clear and fully dissolved. Do not shake.

Refrigerate

Store at 2–8°C for up to 30 days. Do not freeze after reconstitution. Protect from light.

Mechanism of Action

GABA Modulation

Modulates GABAergic transmission — the primary inhibitory neurotransmitter system. Proposed to enhance GABA-A receptor sensitivity without direct agonism, producing anxiolytic effects without benzodiazepine-like dependence or sedation in research models.

Serotonin System

Influences serotonin turnover and 5-HT receptor activity in limbic brain regions. Studied in animal anxiety models (elevated plus maze, Vogel conflict test). Not a direct serotonin agonist.

Enkephalin Stabilisation

Inhibits enzymatic degradation of endogenous enkephalins (endogenous opioid peptides), prolonging their activity. Enkephalins modulate stress response and pain sensitivity in the brain and peripheral nervous system.

BDNF Expression

Increases Brain-Derived Neurotrophic Factor (BDNF) expression in hippocampus and cortex in animal models. BDNF is associated with neuroplasticity, memory consolidation, and resilience to stress.

Research Status

⚠️

Limited Independent Replication

Published Selank research consists primarily of studies from Russian academic institutions. No Phase 1–3 trials are registered on ClinicalTrials.gov as of mid-2026. Independent replication in Western research contexts is very limited. The quality and publication standards of available studies vary widely.

Study Type	Finding	Limitation
Russian RCTs (anxiety)	Reduced anxiety scores vs placebo; comparable to benzodiazepines in some measures	Russian-only journals; limited independent replication
Animal models	Anxiolytic in elevated plus maze; memory-enhancing in learning paradigms	Animal-to-human extrapolation unestablished
Gene expression studies	BDNF upregulation; IL-6 modulation observed	In vitro and animal; no human confirmation

Storage

State	Temperature	Duration	Notes
Lyophilised (powder)	−20°C (freezer)	Up to 24 months	Protect from light and moisture
Reconstituted (liquid)	2–8°C (refrigerator)	Up to 30 days	Do not freeze after reconstitution

⚠️

Disclaimer

This document is an educational research reference only. Selank is not FDA-approved. Published human data is primarily from Russian sources and has not been independently replicated in Western Phase 1–3 trials. By purchasing from LA LAB you confirm you are 18+ and that products are for research purposes only.

Side Effects & What People Report

Semax and Selank share an unusual position: both are approved medicines in Russia and have been used there for decades, but essentially all the research is Russian-language and has never been replicated in Western trials. That is neither proof nor dismissal — it means the evidence exists but has not been independently verified to the standard a Western regulator would require.

Reported	Detail
Nasal irritation	The intranasal route is the researched one.
Drowsiness	Reported by some; Selank is anxiolytic rather than stimulating.
Headache	Occasionally reported, usually mild.
Nothing at all	A common report. Selank is described as subtle — an absence of anxiety rather than a felt effect.

Russian trials describe Selank as anxiolytic without sedation or dependence, which is the main claimed advantage over benzodiazepines. That claim comes from Russian clinical work that has not been independently replicated.

Who Should Avoid Selank

Situation	Why
Pregnancy or breastfeeding	Avoid. No safety data outside Russian clinical use.
Under 18	No data at these doses.
On psychiatric medication	Selank affects GABA and serotonin systems. Speak to a prescriber before combining it with anything.
Using it to replace prescribed anxiety treatment	Do not stop a prescribed medicine for a research peptide. Anxiety is treatable with things that have been properly trialled.

Frequently Asked Questions

Is it addictive?
Russian research reports no dependence or withdrawal, which is the main argument for it over benzodiazepines. That has not been independently verified.

Will it make me drowsy?
It is described as anxiolytic without sedation, though some users do report drowsiness.

Nasal or injected?
Intranasal is the researched route.

How long does it last?
Users describe several hours. It is typically dosed once or twice daily.

Semax and Selank together?
Common practice — Semax for focus, Selank to take the edge off. No trial has tested it.

Can it replace my anxiety medication?
No. Nothing in this guide is a reason to stop a prescribed treatment.

Sources & Research

Zozulya AA et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med 2001;131:315–7.

Kozlovskii II, Danchev ND. The optimizing action of the synthetic peptide Selank on a conditioned active avoidance reflex in rats. Neurosci Behav Physiol 2003;33:639–43.

Volkova A et al. Selank Administration Attenuates Stress-Induced Anxiety in Rats. Front Pharmacol 2016;7:31.

Regulatory status — registered as a medicine in Russia. Not approved by SAHPRA, the FDA or the EMA.

Educational reference only

This document is a research reference, not medical advice and not a treatment plan. Selank is approved in Russia only; its trials have not been replicated to Western regulatory standards. Dose decisions belong to you and your prescriber. Independent certificates of analysis for every LA LAB batch are published under Research → Lab Results, with the Janoshik task number and verification key so you can check them yourself.